FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997333497> ?p ?o ?g. }

• W2997333497 endingPage "590" @default.
• W2997333497 startingPage "582" @default.
• W2997333497 abstract "BackgroundPatients with mechanical heart valves (MHVs) require warfarin to prevent thromboembolism. Dabigatran was less effective than warfarin in patients with MHVs, which prompted a black box warning against the use of direct oral anticoagulants for this indication. However, rivaroxaban and apixaban, which inhibit factor Xa, have not been evaluated in patients with MHVs. To determine whether rivaroxaban and apixaban would be effective, we used MHV-induced thrombin generation assays to compare them with warfarin either alone or in combination with dabigatran.MethodsThrombin generation in the absence or presence of MHV leaflets or sewing ring segments (SRSs) was quantified. Studies were done in control plasma; plasma from patients on warfarin; plasma containing varying concentrations of rivaroxaban, apixaban, or dabigatran alone; or plasma containing rivaroxaban plus dabigatran.ResultsMean endogenous thrombin potential (ETP) increased 1.2-fold, 1.5-fold, and 1.8-fold in the presence of leaflets, Teflon (Terumo Aortic (Sunrise, FL)) SRSs, or Dacron (Terumo Aortic (Sunrise, FL)) SRSs, respectively. Rivaroxaban and apixaban reduced ETP at concentrations above 50 ng/mL but were less effective than warfarin. When rivaroxaban and dabigatran were combined, they suppressed ETP in a more than additive manner.ConclusionsWhereas warfarin suppresses MHV-induced thrombin generation, MHVs induce the generation of factor Xa in concentrations that overwhelm clinically relevant concentrations of rivaroxaban or apixaban. When used in combination, rivaroxaban and dabigatran are more effective than either agent is alone, suggesting that concomitant inhibition of factor Xa and thrombin is better than inhibition of either clotting enzyme alone. Patients with mechanical heart valves (MHVs) require warfarin to prevent thromboembolism. Dabigatran was less effective than warfarin in patients with MHVs, which prompted a black box warning against the use of direct oral anticoagulants for this indication. However, rivaroxaban and apixaban, which inhibit factor Xa, have not been evaluated in patients with MHVs. To determine whether rivaroxaban and apixaban would be effective, we used MHV-induced thrombin generation assays to compare them with warfarin either alone or in combination with dabigatran. Thrombin generation in the absence or presence of MHV leaflets or sewing ring segments (SRSs) was quantified. Studies were done in control plasma; plasma from patients on warfarin; plasma containing varying concentrations of rivaroxaban, apixaban, or dabigatran alone; or plasma containing rivaroxaban plus dabigatran. Mean endogenous thrombin potential (ETP) increased 1.2-fold, 1.5-fold, and 1.8-fold in the presence of leaflets, Teflon (Terumo Aortic (Sunrise, FL)) SRSs, or Dacron (Terumo Aortic (Sunrise, FL)) SRSs, respectively. Rivaroxaban and apixaban reduced ETP at concentrations above 50 ng/mL but were less effective than warfarin. When rivaroxaban and dabigatran were combined, they suppressed ETP in a more than additive manner. Whereas warfarin suppresses MHV-induced thrombin generation, MHVs induce the generation of factor Xa in concentrations that overwhelm clinically relevant concentrations of rivaroxaban or apixaban. When used in combination, rivaroxaban and dabigatran are more effective than either agent is alone, suggesting that concomitant inhibition of factor Xa and thrombin is better than inhibition of either clotting enzyme alone." @default.
• W2997333497 created "2020-01-10" @default.
• W2997333497 creator A5006549987 @default.
• W2997333497 creator A5030887468 @default.
• W2997333497 creator A5054219124 @default.
• W2997333497 creator A5065716918 @default.
• W2997333497 creator A5082464840 @default.
• W2997333497 date "2020-08-01" @default.
• W2997333497 modified "2023-10-18" @default.
• W2997333497 title "Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation" @default.
• W2997333497 cites W1568662837 @default.
• W2997333497 cites W1971011626 @default.
• W2997333497 cites W1979504547 @default.
• W2997333497 cites W1999754767 @default.
• W2997333497 cites W2016875529 @default.
• W2997333497 cites W2023363122 @default.
• W2997333497 cites W2028162842 @default.
• W2997333497 cites W2038706245 @default.
• W2997333497 cites W2051551497 @default.
• W2997333497 cites W2064826963 @default.
• W2997333497 cites W2075196907 @default.
• W2997333497 cites W2094800902 @default.
• W2997333497 cites W2100876297 @default.
• W2997333497 cites W2117582718 @default.
• W2997333497 cites W2126206943 @default.
• W2997333497 cites W2139785591 @default.
• W2997333497 cites W2147953056 @default.
• W2997333497 cites W2166402206 @default.
• W2997333497 cites W2565451362 @default.
• W2997333497 cites W2591532259 @default.
• W2997333497 cites W2749479542 @default.
• W2997333497 cites W2885139761 @default.
• W2997333497 cites W2946663795 @default.
• W2997333497 doi "https://doi.org/10.1016/j.athoracsur.2019.10.091" @default.
• W2997333497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31877292" @default.
• W2997333497 hasPublicationYear "2020" @default.
• W2997333497 type Work @default.
• W2997333497 sameAs 2997333497 @default.
• W2997333497 citedByCount "13" @default.
• W2997333497 countsByYear W29973334972020 @default.
• W2997333497 countsByYear W29973334972021 @default.
• W2997333497 countsByYear W29973334972022 @default.
• W2997333497 countsByYear W29973334972023 @default.
• W2997333497 crossrefType "journal-article" @default.
• W2997333497 hasAuthorship W2997333497A5006549987 @default.
• W2997333497 hasAuthorship W2997333497A5030887468 @default.
• W2997333497 hasAuthorship W2997333497A5054219124 @default.
• W2997333497 hasAuthorship W2997333497A5065716918 @default.
• W2997333497 hasAuthorship W2997333497A5082464840 @default.
• W2997333497 hasBestOaLocation W29973334971 @default.
• W2997333497 hasConcept C126322002 @default.
• W2997333497 hasConcept C164705383 @default.
• W2997333497 hasConcept C2776301958 @default.
• W2997333497 hasConcept C2777292125 @default.
• W2997333497 hasConcept C2778661090 @default.
• W2997333497 hasConcept C2778810321 @default.
• W2997333497 hasConcept C2779161974 @default.
• W2997333497 hasConcept C2780638905 @default.
• W2997333497 hasConcept C42219234 @default.
• W2997333497 hasConcept C57002609 @default.
• W2997333497 hasConcept C71924100 @default.
• W2997333497 hasConcept C89560881 @default.
• W2997333497 hasConcept C98274493 @default.
• W2997333497 hasConceptScore W2997333497C126322002 @default.
• W2997333497 hasConceptScore W2997333497C164705383 @default.
• W2997333497 hasConceptScore W2997333497C2776301958 @default.
• W2997333497 hasConceptScore W2997333497C2777292125 @default.
• W2997333497 hasConceptScore W2997333497C2778661090 @default.
• W2997333497 hasConceptScore W2997333497C2778810321 @default.
• W2997333497 hasConceptScore W2997333497C2779161974 @default.
• W2997333497 hasConceptScore W2997333497C2780638905 @default.
• W2997333497 hasConceptScore W2997333497C42219234 @default.
• W2997333497 hasConceptScore W2997333497C57002609 @default.
• W2997333497 hasConceptScore W2997333497C71924100 @default.
• W2997333497 hasConceptScore W2997333497C89560881 @default.
• W2997333497 hasConceptScore W2997333497C98274493 @default.
• W2997333497 hasFunder F4320319963 @default.
• W2997333497 hasFunder F4320334506 @default.
• W2997333497 hasIssue "2" @default.
• W2997333497 hasLocation W29973334971 @default.
• W2997333497 hasLocation W29973334972 @default.
• W2997333497 hasOpenAccess W2997333497 @default.
• W2997333497 hasPrimaryLocation W29973334971 @default.
• W2997333497 hasRelatedWork W142423038 @default.
• W2997333497 hasRelatedWork W1515125290 @default.
• W2997333497 hasRelatedWork W2000761063 @default.
• W2997333497 hasRelatedWork W2003634422 @default.
• W2997333497 hasRelatedWork W2013904527 @default.
• W2997333497 hasRelatedWork W2049346164 @default.
• W2997333497 hasRelatedWork W2163134764 @default.
• W2997333497 hasRelatedWork W2990629389 @default.
• W2997333497 hasRelatedWork W1570353559 @default.
• W2997333497 hasRelatedWork W3158108456 @default.
• W2997333497 hasVolume "110" @default.
• W2997333497 isParatext "false" @default.
• W2997333497 isRetracted "false" @default.
• W2997333497 magId "2997333497" @default.
• W2997333497 workType "article" @default.